Back to today’s briefing

Story perspectives

Lilly buys AtaiBeckley as Trump, FDA Accelerate Psychedelics

7/19/2026

49 4 Full Breakdown

Summary

Story summary

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion, adding psychedelic candidate BPL-003.
President Donald Trump signed Executive Order 14401 in April urging the FDA to accelerate psychedelic drug reviews.
The FDA issued final guidance on July 13 outlining trial design basics for psychedelic drug investigations.
Definium Therapeutics reported Phase 3 results for LSD-based DT120, lifting shares 50% and aiming for an NDA in six months.

1 of 1

Story summary

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion, adding psychedelic candidate BPL-003.
President Donald Trump signed Executive Order 14401 in April urging the FDA to accelerate psychedelic drug reviews.
The FDA issued final guidance on July 13 outlining trial design basics for psychedelic drug investigations.
Definium Therapeutics reported Phase 3 results for LSD-based DT120, lifting shares 50% and aiming for an NDA in six months.